Extended interval dosing with ocrelizumab in multiple sclerosis – Frederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard, Jonas Munksgaard Berg, Jonna Skov Madsen, Dorte Aalund Olsen, Inga Urbonaviciute, Zsolt Illes, Morten Leif Stilund, Jeppe Romme Christensen, Stephan Bramow, Finn Sellebjerg, Tob
Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab …